The article explores advancements in Acute Myeloid Leukemia (AML) treatment, highlighting breakthroughs in molecular diagnostics, targeted therapies, and personalized approaches. It discusses improved survival rates, challenges with high-risk mutations like FLT3 and TP53, and the evolving role of pathologists in guiding precision medicine for better patient outcomes and potential cures.
“From Treatment to Lab : Clinical Progress in Leukemia and Implications for Pathologists”
